New targets in and potential treatments for cholesterol gallstone disease

Current Opinion in Investigational Drugs

Volumn 7, Issue 4, 2006, Pages 344-348

  Doggrell, Sheila A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

muricholic acid; 6 ethyl chenodeoxycholic acid; Bile acid conjugates; Bile acid transporters; C57L gallstone susceptible mice; Farnesoid X receptor (FXR); FXR mice; Gallstone disease; GW 4064

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6ALPHA ETHYL CHENODEOXYCHOLIC ACID; ABC TRANSPORTER; ARACHIDYL AMINO CHOLANOIC ACID; BETA MURICHOLIC ACID; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL; FARNESOID X RECEPTOR; FATTY ACID; INT 747; MUCIN; SC 435; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

BILE SECRETION; CHOLELITHIASIS; CHOLESTEROL STONE; CLINICAL PROTOCOL; CRYSTALLIZATION; DISEASE MODEL; DRUG ACTIVITY; DRUG CONJUGATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; GALLSTONE FORMATION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

ANIMALS; BILE; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLIC ACIDS; CYCLIC N-OXIDES; DNA-BINDING PROTEINS; GALLSTONES; HUMANS; ISOXAZOLES; MUCINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TROPANES;

EID: 33645810414     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Konikoff FM: Gallstones - approach to medical management. MedGenMed Gastroenterology (2003):October 15. http://www.medscape.com/viewarticle/460309
2. Shaffer EA: The biliary system. Gastroenterology Resource Centre. (2006):March 10. http://gastroresource.com/gitextbook/en/chapter13/13-1-pr.htm
3. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph VWV, Evans RM, Weinberger C: Identification of a nuclear receptor that is activated by farnesol metabolites. Cel (1995) 81(5):687-693.
4. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM: Bile acids: Natural ligands for an orphan nuclear receptor. Science (1999) 284(5418):1365-1368.
5. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B: Identification of a nuclear receptor for bile acids. Science (1999) 284(5418):1362-1365.
6. Sinai CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ: Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell (2000) 102(6):731-744.
7. Moschetta A, Bookout AL, Mangelsdorf DJ: Prevention of cholesterol gallstone disease by FXR agonist in a mouse model. Nat Med (2004) 12(12):1352-1358.
8. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, Jones SA, Willson TM: Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem (2000) 43(16):2971-2974.
9. Wang DQ, Tazuma S: Effect of β-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res (2002) 43(11):1960-1968.
10. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM: 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 46(17):3569-3572.
11. Pellicciari R, Constantino G, Camaioni E, Sadeghpour BM, Entrena A, Wilson TM, Fiorucci S, Clerici C, Gioiello A: Bile acid derivatives as ligands of the farnesold X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem (2004) 47(18):4559-4569.
12. Fiorucci S, Clerici C. Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M et al: Protective effects of 6-ethyl chenodeoxycholic acid, a farnesold X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 313(2):604-612.
13. Gilat T, Somjen GJ, Mazur Y, Leikin-Frenkel A, Rosenberg R, Halpern Z, Konikoff F: Fatty acid bile acid conjugates (FABACs) - new molecules for the prevention of cholesterol crystallisation in bile. Gut (2001) 48(1):75-79.
14. Gilat T, Leiken-Frenkel A, Goldiner L, Laufer H, Halpern Z, Konikoff FM: Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice. Lipids (2001) 36(10):1135-1140.
15. West KL, Ramjiganesh T, Roy S, Keller BT, Fernandez ML: 1-[4-4[4R,5R)-3,3-dibutyl-7-(dimethylamino) -2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin- 5-yl]phenoxyl]butyl]-4-aza-1-azonia-bicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hapatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. J Pharmacol Exp Ther (2002) 303(1):293-299.
16. Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, Salen G: Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7α-hydoxylase. Metabolism (2004) 53(7):927-932.
17. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, van der Valk GJ et al: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 75(3):451-462.
18. -/- mice: A model for low phospholipid-associated cholelithiasis. Hepatology (2004) 38(1):117-128.
19. Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R: ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology (2003) 128(2):452-459.
20. Kullak-Ublick GA: ABC transporter regulation by bile acids: Where PXR maets FXR. J Hepatol (2003) 39(4):628-630.
21. Hoda F, Green RM: Hepatic canalicular membrane transport of bile salt in C57L/J and AKR/J mice: Implications for cholesterol gallstone formation. J Membr Biol (2003) 196(1):9-14.
22. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Amell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS et al: A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 20(3):233-238.
23. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology (2000) 118(2):422-430.
24. Lam P, Wang R, Ling V: Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry (2005) 44(37):12598-12605.
25. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U et al: Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 129(2):476-485.
26. Wang HH, Afdhal NH, Gendler SJ, Wang DQ-H: Targeted disruption of the murine mucin gene 1 decreases susceptibility to chotesterol gallstone formation. J Lipid Res (2004) 45(3):438-447.
27. Gradilone SA, García F, Huebert RC, Tietz PS, Larocca MC, Kierbel A, Carreras FI, Larusso NF, Marinelli RA: Glucagon induces the plasma membrane insertion of functional aquaporin-8 water channels in isolated rat hepatocytes. Hepatology (2003) 37(6):1435-1441.